NI-1701 is under clinical development by Light Chain Bioscience and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect NI-1701’s likelihood of approval (LoA) and phase transition for B-Cell Non-Hodgkin Lymphoma took place on 11 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 11 Mar 2022 decreased NI-1701’s LoA and increased Phase Transition Success Rate (PTSR) for Follicular Lymphoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NI-1701 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

NI-1701 overview

NI-1701 (TG-1801) is under development for the treatment of  acute lymphocytic leukemia (ALL), B-cell non-Hodgkin lymphoma (NHL) including Richter's transformation and follicular lymphoma, chronic lymphocytic leukemia (CLL), and unspecified B-cell lymphoma. It is administered through oral route. The drug candidate is a bi-specific monoclonal antibody, which acts by targeting CD47 and CD19. It is developed based on Kappa Lambda Body technology.

It was also under development for the treatment of diffuse large B-cell lymphoma and melanoma.

Light Chain Bioscience overview

Light Chain Bioscience formerly NovImmune is a biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer. The company’s pipeline products include NI-0101, a toll-like receptor 4 monoclonal antibody for the treatment of chronic inflammation; NI-0401 a monoclonal antibody that targets CD3-epsilon, molecule that sits on the surface of a white blood cell; Emapalumab (NI-0501), a human anti-IFNy monoclonal antibody used for the treatment of hemophagocytic lymphohistiocytosis. It also develops NI-1201, an anti-IL6R monoclonal antibody to treat immune disorders; NI-1401, an Interleukin-17 monoclonal antibody used for the treatment of autoimmune and inflammatory diseases; NI-1701, an anti-CD19/anti-CD47 bispecific antibody that kills tumor cell; and NI-1801 an anti-CD47 that binds mesothelin-positive solid tumors. Light Chain Bioscience develops pipeline products using its proprietary bispecific antibody, and bispecific antibody platform. The company has partnership with Genentech, Tiziana Life Sciences, and Baxalta Inc for developing monoclonal and bispecific antibodies. Light Chain Bioscience is headquartered in Geneva, Switzerland.

Quick View NI-1701 LOA Data

Report Segments
  • Innovator
Drug Name
  • NI-1701
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.